GBIO — Generation Bio Co
NASDAQ · Healthcare · Biotechnology
Generation Bio Co (GBIO) is a biotechnology company listed on NASDAQ. It is led by Cameron Geoffrey McDonough M.D., based in 301 Binney Street, Cambridge, MA, United States, 02142, with about 115 employees. Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Latest reported GBIO revenue for 2025-09-30 was $1.6M. Net income was -$41.2M. Revenue was up 108.4% from 2025-06-30 to 2025-09-30. GBIO currently screens at market cap $25.4M.
Use this GBIO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the GBIO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the GBIO SEC filings page. Lician reads the product cache first so this HTML stays unique to Generation Bio Co even when a live quote feed is slow.
About Generation Bio Co
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
GBIO Key Statistics
Market Cap
$25.37M
EPS
-$1.98
Revenue
$19.89M
Net Income
-$131.67M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+236.9%
Profit Margin
-661.9%
Employees
115
GBIO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $19.89M | $5.90M | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$131.67M | -$126.61M | -$136.64M | -$119.15M |
| EPS (Diluted) | -$1.98 | -$1.96 | -$2.35 | -$2.12 |
Total Assets
$231.20M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$76.30M
Operating Cash Flow
-$88.56M
Free Cash Flow
$0.00
Generation Bio Co Company Information
- President, CEO & Director
- Cameron Geoffrey McDonough M.D.
- Headquarters
- 301 Binney Street, Cambridge, MA, United States, 02142
- Website
- generationbio.com
- Phone
- 617 655 7500
- IPO / Founded
- 2020-06-12
- Sector
- Healthcare
- Industry
- Biotechnology